Evotec AG (NASDAQ:EVTCY) has received a consensus broker rating score of 2.00 (Buy) from the two analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and one has assigned a strong buy rating to the company. Evotec AG’s rating score has improved by 33.3% from 90 days ago as a result of various analysts’ upgrades and downgrades.

Zacks has also assigned Evotec AG an industry rank of 101 out of 265 based on the ratings given to related companies.

A number of brokerages recently weighed in on EVTCY. Zacks Investment Research upgraded shares of Evotec AG from a “hold” rating to a “buy” rating and set a $42.00 target price on the stock in a report on Friday, August 25th. Berenberg Bank restated a “buy” rating on shares of Evotec AG in a report on Wednesday, May 10th. DZ Bank AG restated a “sell” rating on shares of Evotec AG in a report on Thursday, August 17th. Finally, Deutsche Bank AG restated a “neutral” rating on shares of Evotec AG in a report on Wednesday, May 3rd.

TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/08/30/evotec-ag-evtcy-receives-average-rating-of-from-brokerages.html.

Shares of Evotec AG (NASDAQ EVTCY) traded down 3.15% during midday trading on Wednesday, reaching $38.40. 5,402 shares of the company were exchanged. The stock has a market capitalization of $2.81 billion and a price-to-earnings ratio of 65.98. The company’s 50-day moving average price is $31.78 and its 200 day moving average price is $25.26. Evotec AG has a 52-week low of $9.79 and a 52-week high of $39.55.

Evotec AG (NASDAQ:EVTCY) last announced its quarterly earnings data on Thursday, August 10th. The company reported $0.04 EPS for the quarter, missing the Zacks’ consensus estimate of $0.07 by $0.03. The firm had revenue of $58.52 million for the quarter, compared to analyst estimates of $50.06 million.

Evotec AG Company Profile

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.

Get a free copy of the Zacks research report on Evotec AG (EVTCY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.